Meningeal lymphatic vasculature,a general target for glioblastoma therapy?  

作　　者：Changping Zhou Han Xu Jincai Luo 

机构地区：[1]Laboratory of Vascular Biology,Institute of Molecular Medicine,College of Future Technology,Beijing Key Laboratory of Cardiometabolic Molecular Medicine,Peking University,Beijing 100871,China

出　　处：《Fundamental Research》2024年第2期267-269,共3页自然科学基础研究（英文版）

基　　金：supported by research grants from the National Natural Science Foundation of China(81930011,91739304,and 31821091);the National Key R&D Program of China(2019YFA0801603);supported by a Postdoctoral Fellowship of the Peking-Tsinghua Center for Life Sciences;the China Postdoctoral Science Foundation(2022T150012).

摘　　要：Glioblastoma(GBM)causes nearly universal mortality as a result of the failure of conventional therapies including surgical resection,targeted radiation therapy,and chemotherapy.An increasingly important treatment option is combining immunotherapy with other therapies in both preclinical and clinical studies.The central nervous system(CNS)has been historically considered an immune privileged area,but increasing evidence,including the recent rediscovery of meningeal lymphatic vessels(MLVs),has overturned this notion.MLVs are populated by multiple immune cells and connect the CNS to the periphery by draining cerebrospinal fluid with soluble CNS antigens and immune cells into cervical lymph nodes.In the past few years,more and more studies have indicated that MLVs are involved in the regulation of inflammation and the immune response in the pathogenesis of various CNS diseases including GBM.Here,we explore the critical interlinkages between MLVs and GBM therapies including chemotherapy,radiotherapy and immunotherapy,and propose the meningeal lymphatic vasculature as a general target for GBM therapy.

关 键 词：Meningeal lymphatic vessels GLIOBLASTOMA IMMUNITY Vascular endothelial growth factor C Immune modulation 

分 类 号：R739.41[医药卫生—肿瘤]